{"entity":{"id":"paper-budnik-novelna-proteomics-bmj-oncol-2024","kind":"paper","name":"Novel proteomics-based plasma test for early detection of multiple cancers in the general population","aka":[],"tldr":"Novelna's discovery study: panels of ten blood proteins, one for men and one for women, separated 440 people with and without 18 early cancers with high accuracy in a small laboratory comparison.","summary":"Budnik and colleagues measured more than 3,000 plasma proteins by proximity extension assay in 440 people, healthy or diagnosed with 18 early-stage solid tumours, and selected sex-specific panels. The 10-protein detection panels reached an area under the curve of 0.98 in males and 0.983 in females; at stage I and 99% specificity they identified 93% (95% CI 79 to 100) of cancers among males and 84% (68 to 100) among females. 150-protein localisation panels identified the tissue of origin of most cancers in more than 80% of cases.","asOf":"2026-10-29","links":[{"label":"BMJ Oncology 2024","url":"https://doi.org/10.1136/bmjonc-2023-000073"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/39886137/"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["mced","proteomics"],"targets":[],"drugs":["novelna-protein-test"],"companies":["novelna"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"BMJ Oncology","year":2024,"doi":"10.1136/bmjonc-2023-000073","pmid":"39886137","authors":"Budnik B, Amirkhani H, Forouzanfar MH, Afshin A","paperType":"translational","findings":["10-protein panels: area under the curve 0.98 (males) and 0.983 (females).","Stage I sensitivity at 99% specificity: 93% in males, 84% in females, with wide confidence intervals.","Tissue of origin identified in more than 80% for most cancers."],"whatItMeans":"Very high figures from a small discovery set in which the same samples helped choose the proteins; figures like these usually fall when a test meets a larger, independent population.","caveats":["440 people across 18 cancer types, so few cases per cancer; wide confidence intervals.","No independent validation in the paper.","Authors include Novelna's founder."],"changedPractice":false,"participants":440},"route":"/key-papers/paper-budnik-novelna-proteomics-bmj-oncol-2024/","neighbours":{"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"}],"technology":[{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"drug":[{"id":"novelna-protein-test","kind":"drug","name":"Novelna sex-specific protein test","route":"/drugs/novelna-protein-test/"}],"company":[{"id":"novelna","kind":"company","name":"Novelna","route":"/companies/novelna/"}]}}